Beijing SL Pharmaceutical Co Ltd (002038) — Financial Flexibility Index
Beijing SL Pharmaceutical Co Ltd (002038) has a Financial Flexibility Index of 0.24x as of September 2025. Free cash flow of CN¥77.90 Million (operating CF CN¥66.55 Million minus capex CN¥11.35 Million) represents 0% of total liabilities (CN¥327.96 Million). Check cash flow reinvestment rate of Beijing SL Pharmaceutical Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Beijing SL Pharmaceutical Co Ltd Financial Flexibility Index (2003–2025)
Historical Financial Flexibility Index trend for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Beijing SL Pharmaceutical Co Ltd.
Annual Financial Flexibility Index for Beijing SL Pharmaceutical Co Ltd (2003–2025)
Year-by-year free cash flow to debt coverage for Beijing SL Pharmaceutical Co Ltd. Explore Beijing SL Pharmaceutical Co Ltd (002038) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.51x | CN¥450.63 Million | CN¥257.66 Million | CN¥883.49 Million | ▼ -64.5% |
| 2024 | 1.44x | CN¥572.87 Million | CN¥225.49 Million | CN¥398.37 Million | ▼ -0.9% |
| 2023 | 1.45x | CN¥678.56 Million | CN¥460.20 Million | CN¥467.72 Million | ▲ +4.0% |
| 2022 | 1.40x | CN¥553.31 Million | CN¥389.82 Million | CN¥396.60 Million | ▼ -13.6% |
| 2021 | 1.62x | CN¥701.54 Million | CN¥464.63 Million | CN¥434.23 Million | ▼ -1.4% |
| 2020 | 1.64x | CN¥671.79 Million | CN¥415.84 Million | CN¥410.09 Million | ▼ -29.5% |
| 2019 | 2.32x | CN¥938.61 Million | CN¥665.83 Million | CN¥403.76 Million | ▲ +53.3% |
| 2018 | 1.52x | CN¥712.55 Million | CN¥485.17 Million | CN¥469.73 Million | ▼ -29.0% |
| 2017 | 2.14x | CN¥610.37 Million | CN¥380.72 Million | CN¥285.67 Million | ▼ -42.4% |
| 2016 | 3.71x | CN¥561.07 Million | CN¥396.86 Million | CN¥151.19 Million | ▼ -13.2% |
| 2015 | 4.28x | CN¥634.55 Million | CN¥504.87 Million | CN¥148.40 Million | ▼ -4.3% |
| 2014 | 4.47x | CN¥616.02 Million | CN¥465.00 Million | CN¥137.92 Million | ▲ +20.3% |
| 2013 | 3.71x | CN¥456.89 Million | CN¥347.41 Million | CN¥123.09 Million | ▼ -39.6% |
| 2012 | 6.15x | CN¥646.49 Million | CN¥398.60 Million | CN¥105.17 Million | ▲ +2.9% |
| 2011 | 5.97x | CN¥301.64 Million | CN¥228.59 Million | CN¥50.52 Million | ▼ -21.0% |
| 2010 | 7.55x | CN¥281.18 Million | CN¥238.13 Million | CN¥37.22 Million | ▲ +35.5% |
| 2009 | 5.57x | CN¥204.86 Million | CN¥174.41 Million | CN¥36.75 Million | ▼ -33.7% |
| 2008 | 8.41x | CN¥217.93 Million | CN¥194.32 Million | CN¥25.91 Million | ▲ +154.0% |
| 2007 | 3.31x | CN¥114.98 Million | CN¥88.36 Million | CN¥34.71 Million | ▼ -4.2% |
| 2006 | 3.46x | CN¥122.50 Million | CN¥57.55 Million | CN¥35.41 Million | ▼ -37.1% |
| 2005 | 5.50x | CN¥128.72 Million | CN¥47.48 Million | CN¥23.42 Million | ▲ +218.3% |
| 2004 | 1.73x | CN¥49.00 Million | CN¥31.26 Million | CN¥28.38 Million | ▲ +35.1% |
| 2003 | 1.28x | CN¥46.99 Million | CN¥30.55 Million | CN¥36.78 Million | — |